- Home
- BATL vs CLGN Comparison
BATL vs CLGN Comparison
Compare BATL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- CLGN
- Stock Information
- Founded
- BATL 1987
- CLGN 2004
- Country
- BATL United States
- CLGN Israel
- Employees
- BATL N/A
- CLGN N/A
- Industry
- BATL Oil & Gas Production
- CLGN Industrial Specialties
- Sector
- BATL Energy
- CLGN Health Care
- Exchange
- BATL Nasdaq
- CLGN Nasdaq
- Market Cap
- BATL 20.6M
- CLGN 20.4M
- IPO Year
- BATL N/A
- CLGN N/A
- Fundamental
- Price
- BATL $1.50
- CLGN $1.38
- Analyst Decision
- BATL
- CLGN Strong Buy
- Analyst Count
- BATL 0
- CLGN 2
- Target Price
- BATL N/A
- CLGN $11.50
- AVG Volume (30 Days)
- BATL 3.1M
- CLGN 147.4K
- Earning Date
- BATL 08-13-2025
- CLGN 08-19-2025
- Dividend Yield
- BATL N/A
- CLGN N/A
- EPS Growth
- BATL N/A
- CLGN N/A
- EPS
- BATL N/A
- CLGN N/A
- Revenue
- BATL $191,498,000.00
- CLGN $2,472,000.00
- Revenue This Year
- BATL N/A
- CLGN $2,177.67
- Revenue Next Year
- BATL N/A
- CLGN $56.52
- P/E Ratio
- BATL N/A
- CLGN N/A
- Revenue Growth
- BATL N/A
- CLGN N/A
- 52 Week Low
- BATL $1.05
- CLGN $1.35
- 52 Week High
- BATL $6.89
- CLGN $5.48
- Technical
- Relative Strength Index (RSI)
- BATL 45.32
- CLGN 40.54
- Support Level
- BATL $1.30
- CLGN $1.35
- Resistance Level
- BATL $3.21
- CLGN $1.54
- Average True Range (ATR)
- BATL 0.44
- CLGN 0.16
- MACD
- BATL -0.04
- CLGN -0.03
- Stochastic Oscillator
- BATL 9.58
- CLGN 4.56
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.